Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 648 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR For AYAs with Advanced Cancer, Study Finds Serious Communication Gaps about... April 15, 2025 An integral part of research September 21, 2022 ESMO Announces Winners of its Awards 2020 [ESMO Press Release] August 25, 2020 EMA Recommends Granting a Marketing Authorisation for Lutetium (177lu) Chloride August 4, 2022 Load more HOT NEWS When You Have Cancer and You’re a Parent: “Your Stories” Podcast Drug Combination May Have Potential for Cancers with TP53 Mutations Teenage (…and young adult) kicks Getting cancer services back on track during the COVID-19 pandemic
